Table 2.
Lists all the inhibitory, activating KIR genes, and pseudogenes according to the time to treatment failure (TTF ≤6 or ≥10 months).
| Inhibitory KIR genes presence | TTF < 6 months | TTF > 10 months | |
|---|---|---|---|
| 2DL1 | Yes | 18 (50%) | 18 (50%) |
| No | 2 (66.7%) | 1 (33.3%) | |
| 2DL2 | Yes | 12 (48%) | 13 (52%) |
| No | 8 (57.1%) | 6 (42.9%) | |
| 2DL3 | Yes | 18 (51.4%) | 17 (48.6%) |
| No | 2 (50%) | 2 (50%) | |
| 2DL5 | Yes | 10 (43.5%) | 13 (56.5) |
| No | 10 (62.5%) | 6 (37.5%) | |
| 3DL1 | Yes | 19 (54.3%) | 16 (45.7%) |
| No | 1 (25%) | 3 (75%) | |
| 3DL2a | Yes | 20 (51.3%) | 19 (48.7%) |
| No | 0 | 0 | |
| 3DL3a | Yes | 20 (51.3%) | 19 (48.7%) |
| No | 0 | 0 | |
| 2DL4a | Yes | 20 (51.3%) | 19 (48.7%) |
| No | 0 | 0 | |
| Activating KIR genes presence | TTF < 6 months | TTF > 10 months | |
| 2DS1 | Yes | 9 (37.5%) | 15 (62.5%) |
| No | 11 (73.3%) | 4 (26.7%) | |
| 2DS2 | Yes | 12 (48%) | 13 (52%) |
| No | 8 (57.1%) | 6 (42.9%) | |
| 2DS3 | Yes | 3 (27.3%) | 8 (72.7%) |
| No | 17 (60.7%) | 11 (39.3%) | |
| 2DS4 | Yes | 19 (52.8%) | 17 (47.2%) |
| No | 1 (33.3%) | 2 (66.7%) | |
| 2DS5 | Yes | 9 (47.4%) | 10 (52.6%) |
| No | 11 (55%) | 9 (45%) | |
| 3DS1 | Yes | 9 (45%) | 11 (55%) |
| No | 11 (57.9%) | 8 (42.1%) | |
| 2DL4a | Yes | 20 (51.3%) | 19 (48.7%) |
| No | 0 | 0 | |
| KIR pseudogene presence | TTF < 6 months | TTF > 10 months | |
| 2DP1 | Yes | 18 (51.4%) | 17 (48.6%) |
| No | 2 (50%) | 2 (50%) | |
| 3DP1a | Yes | 20 (51.3%) | 19 (48.7%) |
| No | 0 | 0 | |
aPresent in 100% of the population.